In an interview with The Center for Biosimilars®, Angus Worthing, MD, FACP, FACR, chair of the American College of Rheumatology (ACR) Government Affairs Committee, discussed the letter recently sent to HHS addressing physician concerns with proposed legislation.
Last week, 9 physician groups sent a joint letter to HHS Secretary Alex Azar to voice concerns about the president’s 2019 budget and the Council of Economic Advisers’ drug plan.
When asked what the burden on the patient would be if practitioners have to stop prescribing biologic therapies altogether due to concerns outlined in the letter, Angus Worthing, MD, FACP, FACR, chair of the American College of Rheumatology (ACR) Government Affairs Committee, told the Center for Biosimilars® in an email that patients losing access to biologic therapy can be a crisis.
“Most people currently taking a biologic have spent years obtaining a diagnosis, then trying initial treatment with pills or other drugs, which may have been inadequate or caused side effects, and now if they’re doing well, stopping biologic treatment is likely to cause a flare of disease… so, once a person’s disease is well-controlled with biologic therapy, that treatment shouldn’t be stopped for nonmedical reasons,” Worthing wrote.
Proposed legislation, such as President Donald Trump’s budget, could impact patients starting to use biosimilars, he added. “Reducing access to biosimilars at this time could possibly threaten to reduce demand for biosimilars and prevent their reason for being, which is to reduce biologic drug prices. This would be an unfortunate unintended consequence of a plan geared toward reducing biologic drug prices,” said Worthing.
In the letter, the groups also urged HHS to repeal the sequester cuts to Medicare Part B reimbursements. When asked what he has personally seen happen in his own practice due to the sequester cuts, Worthing noted, “The large group practice in which I practice has leveraged efficiencies in order to continue to provide Part B drug services to Medicare beneficiaries despite the sequester’s nearly 30% reimbursement cut; however, doctors in small or underserved communities have had to stop providing these drugs because of the razor-thin margins that threaten viability. Their patients have been forced to different sites of service like hospitals, which can cost the system more money or can sometimes be inconvenient or unfamiliar to patients.”
Finally, Worthing commended the White House for prioritizing the reduction of high drug prices. “The ACR and other stakeholders stand ready to work with the administration to do just that; however, we want to make sure proposals don’t have the unintended consequence of reducing access to these critical treatments for our patients.”
FDA and Industry Experts Unpack Biosimilar Device Requirements
October 23rd 2024At the GRx+Biosims 2024 conference, a panel of industry experts and FDA officials discussed evolving device requirements for biosimilars and interchangeable biosimilars, highlighting new approaches to comparative use human factors studies, regulatory challenges, and alternative validation methods.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Eye on Pharma: Aflibercept Legal Drama; PBM, Humira Biosimilars; Denosumab Regulatory Review
October 15th 2024Regeneron appeals legal decision after judge refuses to block an aflibercept biosimilar; Prime Therapeutics, a pharmacy benefit manager (PBM), becomes the latest to offer biosimilars referencing Humira (adalimumab) at a low cost; the FDA and European Medicines Agency accept a denosumab biosimilar candidate for review.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Sandoz Report: A Unified Approach to Overcoming Drug Shortages
October 10th 2024A report from Sandoz emphasizes the need for collaboration among stakeholders to eliminate drug shortages impacting over 90% of hospital systems in the US, recommending policy changes and actions to address the ongoing issue, which has caused treatment delays and increased costs.